Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 4/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | USP10 | Q14694 | 1/20 | 0.40 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31158388 | 1.00 | PTPN2 (0.51) | PTPN2HDAC1POLBLMNASMN1; SMN2 | |
| SCHEMBL19433701 | 0.86 | PTPN2 (0.51) | PTPN2POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL31158466 | 0.86 | PTPN2 (0.51) | PTPN2POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL28538335 | 0.86 | PTPN2 (0.58) | PTPN2POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL19433565 | 0.84 | LMNA (0.45) | PTPN2HDAC1POLBLMNASMN1; SMN2 | |
| SCHEMBL16396141 | 0.84 | HDAC3 (0.46) | PTPN2HDAC1POLBLMNASMN1; SMN2 | |
| SCHEMBL16396006 | 0.84 | PTPN2 (0.45) | PTPN2HDAC1POLBLMNASMN1; SMN2 | |
| SCHEMBL16396400 | 0.84 | PTPN2 (0.43) | PTPN2HDAC1POLBLMNASMN1; SMN2 | |
| SCHEMBL29924771 | 0.81 | PTPN2 (0.45) | PTPN2HDAC1POLBLMNASMN1; SMN2 | |
| SCHEMBL29149728 | 0.81 | PTPN2 (0.45) | PTPN2HDAC1POLBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125346-A1 | Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-3227271-B1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RES LAB (KR) | 2025-08-13 | — | — | EP | disclosed |
| CN-107001345-B | Heterocyclic derivatives and use thereof | 株式会社C&C新药研究所 | 2021-03-02 | — | — | CN | disclosed |
| US-10633394-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2020-04-28 | — | — | US | disclosed |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2020-02-18 | — | — | US | disclosed |
| US-20190119297-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2019-04-25 | — | — | US | disclosed |
| EP-3004057-B1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STAT 3 INHIBITORS | C&C RES LAB (KR) | 2018-07-25 | — | — | EP | disclosed |
| EP-3227271-A2 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C Research Laboratories (KR) | 2017-10-11 | — | — | EP | disclosed |
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2016-04-21 | — | — | US | disclosed |
| EP-3004057-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C Research Laboratories (KR) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014196793-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633394-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, STAT5A | PTPN2 329/4885HDAC1 144/4885POLB 4570/4885 |
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | STAT3, JAK2, STAT5A | PTPN2 329/4885HDAC1 144/4885POLB 4570/4885 |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, STAT5A | PTPN2 329/4885HDAC1 144/4885POLB 4570/4885 |
| US-20260125346-A1 | Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease | NR3C1, NR3C2, PIK3R4 | PTPN2 811/4885HDAC1 236/4885POLB 1081/4885 |
| US-20190119297-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | STAT3, JAK2, STAT5A | PTPN2 329/4885HDAC1 144/4885POLB 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.